This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

PRELIMINARY REPORT

WILLIAM H. GUY, M.D.; BERNHARD A. GOLDMANN, M.D.; GEORGE P. GANNON, M.D.

Arch Derm Syphilol. 1943;47(2):235-238.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

For a number of years it has been known that arsenoxide is the effective end product of arsphenamine and neoarsphenamine which produces the curative results in the treatment of syphilis. This drug was produced by Ehrlich in his experiments with various compounds of arsenic but was never used as such until recently because of its great toxicity and instability. Mapharsen is an example of an effective form of arsenoxide with low toxicity.

For a period of eighteen months we at the University of Pittsburgh have been studying the effects of phenarsine hydrochloride in established cases of syphilis.

CHEMISTRY AND PHARMACOLOGY¹

Two single dosage forms of phenarsine hydrochloride are available. The smaller dose contains 0.045 Gm. of 3-amino-4-hydroxyphenyldichlorarsine hydrochloride, which yields 0.0308 Gm. of the active principle, 3-amino-4-hydroxyphenylarsenoxide (arsenoxide). A dose of 0.04 Gm. of mapharsen yields exactly the same amount of active principle. The larger dose of phenarsine hydrochloride . . . [Full Text PDF of this Article]

Author Affiliations
PITTSBURGH

From the Department of Dermatology and Syphilology, University of Pittsburgh School of Medicine.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?